Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis

被引：21
|
作者：
Song, Gwan G. [1 ]
Lee, Young H. [1 ]
机构：
[1] Korea Univ, Seoul, South Korea
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 378卷 / 02期
关键词：
D O I：
10.1056/NEJMc1714810
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：194 / 194
页数：1
相关论文
共 50 条
  • [1] Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
    Saag, Kenneth G.
    Petersen, Jeffrey
    Brandi, Maria Luisa
    Karaplis, Andrew C.
    Lorentzon, Mattias
    Thomas, Thierry
    Maddox, Judy
    Fan, Michelle
    Meisner, Paul D.
    Grauer, Andreas
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (15): : 1417 - 1427
  • [2] Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial
    Black, DM
    Thompson, DE
    Bauer, DC
    Ensrud, K
    Musliner, T
    Hochberg, MC
    Nevitt, MC
    Suryawanshi, S
    Cummings, SR
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11): : 4118 - 4124
  • [3] In postmenopausal women with osteoporosis, romosozumab followed by alendronate reduced fractures vs alendronate alone
    Hirsch, Calvin
    [J]. ANNALS OF INTERNAL MEDICINE, 2018, 168 (02) : JC3 - JC3
  • [4] Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis
    Cosman, F.
    Crittenden, D. B.
    Adachi, J. D.
    Binkley, N.
    Czerwinski, E.
    Ferrari, S.
    Hofbauer, L. C.
    Lau, E.
    Lewiecki, E. M.
    Miyauchi, A.
    Zerbini, C. A. F.
    Milmont, C. E.
    Chen, L.
    Maddox, J.
    Meisner, P. D.
    Libanati, C.
    Grauer, A.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [5] Romosozumab versus teriparatide in premenopausal women with idiopathic osteoporosis
    Lee, Seunghyun
    Shin, Sungjae
    Hong, Namki
    Lim, Jung Soo
    Rhee, Yumie
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 166 - 166
  • [6] Osteoporosis: Romosozumab for Fracture Prophylaxis
    Krome, Susanne
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2017, 142 (06) : 396 - 396
  • [7] Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
    Leder, Benjamin Z.
    Mitlak, Bruce
    Hu, Ming-Yi
    Hattersley, Gary
    Bockman, Richard S.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (03): : 938 - 943
  • [8] A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk
    Saag, Kenneth
    Petersen, Jeffrey
    Brandi, Maria Luisa
    Karaplis, Andrew
    Lorentzon, Mattias
    Thomas, Thierry
    Maddox, Judy
    Fan, Michelle
    Meisner, Paul D.
    Grauer, Andreas
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [9] COST EFFECTIVENESS OF ROMOSOZUMAB FOLLOWED BY ALENDRONATE VERSUS TERIPARATIDE IN THE TREATMENT OF SEVERE OSTEOPOROSIS IN GREECE
    Golnas, P.
    Relakis, J.
    Kountouris, V
    Golna, C.
    Makras, P.
    Willems, D.
    Souliotis, K.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S57 - S57
  • [10] T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial
    Cosman, Felicia
    Lewiecki, E. Michael
    Ebeling, Peter R.
    Hesse, Eric
    Napoli, Nicola
    Crittenden, Daria B.
    Rojeski, Maria
    Yang, Wenjing
    Libanati, Cesar
    Ferrari, Serge
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
12345